N-{(1S,2R,3S,4R)-4-[2-((1S,3R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide | 884652-89-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: N-{(1S,2R,3S,4R)-4-[2-((1S,3R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide
• 英文别名: N-{(1S,2R,3S,4R)-4-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide；N-{(1S,2R,3S,4R)-4-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenylethylamino)-purin-9-yl]-2,3-dihydroxycyclopentyl}propionamide；N-[(1S,2R,3S,4R)-4-[2-[(3R)-3-aminopyrrolidin-1-yl]-6-(2,2-diphenylethylamino)purin-9-yl]-2,3-dihydroxycyclopentyl]propanamide
• CAS: 884652-89-5
• 化学式: C₃₁H₃₈N₈O₃
• 分子量: 570.695
• InChiKey: BNGCBNFCYFRFLY-FSNRGTNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  154
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  N-{(1S,2R,3S,4R)-4-[2-((1S,3R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide 、 N-氰基羰亚胺二苯基酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 (1S,2R,3S,4R)-4-{6-(2,2-diphenylethylamino)-2-[(R)-3-(3-cyano-2-phenylisoureido)pyrrolidin-1-yl]purin-9-yl}-2,3-dihydroxycyclopentanecarboxylic acid ethylamide
  参考文献：
  名称：

  Organic Compounds

  摘要：

  化合物的公式（I）或其立体异构体或药用可接受的盐，以及它们的制备和用途作为药物，其中R1、R2和R3如本文所定义。

  公开号：

  US20100286126A1
• 作为产物：
  描述：

  (1S,2R,3S,5R)-3-Amino-5-[2-chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-cyclopentane-1,2-diol trifluoroacetate 在 盐酸 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 二甲基亚砜 为溶剂， 反应 73.0h， 生成 N-{(1S,2R,3S,4R)-4-[2-((1S,3R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide
  参考文献：
  名称：

  WO2007/121924

  摘要：

  公开号：

文献信息

• Adenosine Derivatives as A2A Receptor Agonists
  申请人：Novartis AG

  公开号：EP1903044A1

  公开（公告）日：2008-03-26

  A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U1, U2, R1a, R1b, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式（I）的化合物，或其立体异构体或药学上可接受的盐，其中A，U1，U2，R1a，R1b，R2和R3的含义如规范中所示，适用于治疗通过激活腺苷A2A受体介导的情况，特别是炎症性或阻塞性呼吸道疾病。还描述了含有这些化合物的药物组合物和制备这些化合物的过程。
• Purine Derivatives for Use as Adenosin A-2A Receptor Agonists
  申请人：Fairhurst Robin Alec

  公开号：US20080200483A1

  公开（公告）日：2008-08-21

  Compounds of formula I in free or salt form, wherein R 1 , R 2 and R 3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A 2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物，无论是自由形式还是盐形式，其中R1、R2和R3具有规范中指定的含义，对于治疗由腺苷A2A受体激活介导的炎症或阻塞性呼吸道疾病是有用的。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS
  申请人：Fairhurst Robin Alec

  公开号：US20090325967A1

  公开（公告）日：2009-12-31

  A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U 1 , U 2 , R 1a , R 1b , R 2 and R 3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A 2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式(I)的化合物，或其立体异构体或药学上可接受的盐，式(1)的化合物，或其立体异构体或药学上可接受的盐，其中A、U1、U2、R1a、R1b、R2和R3的含义如规范中所示，用于治疗由腺苷A2A受体激活介导的疾病，特别是炎症性或阻塞性呼吸道疾病。还描述了含有该化合物的药物组合物和制备该化合物的过程。
• Purine derivatives for use as adenosine A-2A receptor agonists
  申请人：Novartis AG

  公开号：US08163754B2

  公开（公告）日：2012-04-24

  Compounds of formula I in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2和R3的含义如规范中所示，可用于治疗由腺苷A2A受体激活介导的疾病，特别是炎症性或阻塞性空气道疾病。还描述了包含这些化合物的制药组合物以及制备这些化合物的过程。
• Organic compounds
  申请人：Novartis AG

  公开号：US08193164B2

  公开（公告）日：2012-06-05

  A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, wherein, R1a, R1b, R2a, R2b, U1, U2, X1, X2 and L are as defined herein.

  式（I）的化合物，或其立体异构体或药学上可接受的盐，其中，R1a、R1b、R2a、R2b、U1、U2、X1、X2和L的定义如本文所述。